April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Intravitreal Bevacizumab Prior to Vitrectomy for Diabetic Traction Retinal Detachment
Author Affiliations & Notes
  • E. Du
    Ophthalmology, Henry Ford Health System, Detroit, Michigan
  • R. Pokroy
    Ophthalmology, Henry Ford Health System, Detroit, Michigan
  • Y. Li
    Ophthalmology, Henry Ford Health System, Detroit, Michigan
  • P. A. Edwards
    Ophthalmology, Henry Ford Health System, Detroit, Michigan
  • U. R. Desai
    Ophthalmology, Henry Ford Health System, Detroit, Michigan
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 5077. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      E. Du, R. Pokroy, Y. Li, P. A. Edwards, U. R. Desai; Intravitreal Bevacizumab Prior to Vitrectomy for Diabetic Traction Retinal Detachment. Invest. Ophthalmol. Vis. Sci. 2010;51(13):5077.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To assess the efficacy and safety of preoperative intravitreal bevacizumab (IVB) before vitrectomy for diabetic tractional retinal detachment (TRD).

Methods: : Using ICD-9 codes, we located charts of patients with diabetic TRD who underwent 3-port 20 gauge vitrectomy by a single surgeon between January 2004 and January 2009. Eyes receiving IVB were compared with those not. The following outcomes were compared: visual acuity (VA), duration of surgery and complication rates.

Results: : Ninety-nine eyes of 90 patients were included in the analysis. Thirty-four patients received IVB an average of 11.5 (range, 3-30) days previtrectomy. Age was 46.5 and 51.6 in the IVB and non-IVB groups, respectively. Visual acuity improved significantly in both groups: from 20/617 to 20/62 in the IVB group, and from 20/443 to 20/86 in the non-IVB group (P=0.11 between groups). Operating time and postoperative complications (glaucoma, retinal detachment, revitrectomy rate) were similar in both groups. Upon comparing IVB and non-IVB eyes in younger patients (< 40), operating time was shorter (P=0.02) and a trend to better VA in the IVB group was seen.

Conclusions: : We conclude that preoperative IVB is a useful adjunct to vitrectomy in eyes with severe proliferative diabetic retinopathy complicated by TRD. The efficacy is most apparent in young diabetics.

Keywords: diabetic retinopathy • retinal detachment • vitreoretinal surgery 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×